- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 20
Here are the top 5 biosimilars articles for the week of April 20, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 20, 2020.
Number 5: A Swedish company that wants to bring a ranibizumab biosimilar to market said it may finish trial enrollment despite the pandemic.
Number 4: 2020 has already seen 4 biosimilar launches in the United States, with potentially several more on the way. Although, the coronavirus disease 2019 (COVID-19) pandemic has introduced a wild card to the mix, according to presenters for the AMCP eLearning Days virtual meeting.
Number 3: Education is often noted as a barrier to uptake, but a prominent pharmacy expert said multiple private and public policies also stand between patients and biosimilars.
Number 2: A percentage of oncology pharmacy practitioners report their guidance on biosimilars is influential with clinicians, but many feel their knowledge of biosimilars is deficient in a number of important areas.
Number 1: In partnership with Samsung Bioepis, Merck has launched the trastuzumab biosimilar, Ontruzant, which marks the fifth trastuzumab biosimilar available on the US market.
To read all of these articles and more, visit centerforbiosimilars.com.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
